Abstract
Lung gene therapy for cystic fibrosis disease has not been successful due to several challenges such as the absence of an appropriate vector. Therefore, optimal delivery of emerging therapeutics to airway epithelial cells demands suitable non-viral systems. In this work, we describe the formulation and the physicochemical investigation of biocompatible and biodegradable polymeric nanoparticles (NPs), including PLGA and chitosan (animal and non-animal), as novel methods for the safe and efficient delivery of CFTR-specific locked nucleic acids (LNAs).
| Original language | English (Ireland) |
|---|---|
| Journal | Materials |
| DOIs | |
| Publication status | Published - 13 Jan 2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- biopolymers
- cell therapy
- chitosan
- cystic fibrosis
- cystic fibrosis transmembrane conductance regulator (cftr)
- disease
- drug-delivery
- dry powder formulations
- in-vitro
- locked-nucleic acid (lna)
- lung gene delivery
- nanoparticles
- particle-size
- plga
- sirna
- systems
- transmembrane conductance regulator
Fingerprint
Dive into the research topics of 'Biopolymer-based nanoparticles for cystic fibrosis lung gene therapy studies'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver